Our cash operating expenses or combined R&D and SG&A expenses for the 2026 totaled $3.9 million compared to $2.9 million for ...

Kyntra Bio, Inc. (NASDAQ: KYNB) Q1 2026 Earnings Call Transcript May 11, 2026 Kyntra Bio, Inc. misses on earnings expectations. Reported EPS is $-3.76 EPS, expectations were $-3.36.

Ultragenyx Pharmaceutical Inc. ( RARE) Bank of America Global Healthcare Conference 2026 May 12, 2026 5:20 PM EDT I'm one of the biotech analysts here at BofA. Our next presenting company is ...

Good afternoon, everyone, and thank you for joining us today to discuss Kyntra Bio, Inc.’s first quarter 2026 financial and business results. I am Gaia Vasiliver-Shamis from LifeSci Advisors. Joining ...

Red light therapy may be beneficial for back pain management. Learn our top picks of RLT for back pain devices in this review ...

WILMINGTON, Del., May 12, 2026 (GLOBE NEWSWIRE) -- Inhibikase Therapeutics, Inc. (Nasdaq: IKT) (“Inhibikase” or “Company”), a clinical-stage pharmaceutical company developing IKT-001 for Pulmonary ...

Axsome Therapeutics (NASDAQ:AXSM) held its first-quarter earnings conference call on Monday. Below is the complete transcript from the call. This content is powered by Benzinga APIs. For comprehensive ...

Walking can strengthen the muscles supporting your spine, improving stability and reducing lower back pain. Regular exercise including walking may reduce lower back pain flare-ups by almost 50%.

Upper left back pain can stem from muscle strain, herniated discs, spinal conditions like scoliosis or stenosis, poor posture, or organ-related issues such as pancreatitis, kidney stones, or heart ...

Earnings call Amgen delivered a strong Q1 2026, with 4% YoY product sales growth and six key growth drivers rising 24% to account for 70% of sales. Management raised full-year 2026 revenue guidance to ...

An office chair is one of those things people tolerate while working from home until they don’t. It’s not dramatic. It’s the slow creep — shifting in your seat, leaning forward, sitting back, ...

Earnings call Bristol Myers Squibb delivered solid Q1 2026 results, with total revenue up 1% YoY to $11.5B and growth portfolio sales rising 9% to $6.2B. Management reaffirmed full-year guidance and ...